Latest & greatest articles for simvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on simvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on simvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for simvastatin

1. Simvastatin (Zocor)

Simvastatin (Zocor) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing the Clinical

2020 Health Canada - drugs and medical devices

2. Ezetimibe and ezetimibe/simvastatin for primary hypercholesterolaemia

Ezetimibe and ezetimibe/simvastatin for primary hypercholesterolaemia '); } else { document.write(' '); } ACE | Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia Search > > Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia - Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia Published on 2 May 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Ezetimibe 10 mg tablet (...) Ezetimibe 10 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications. SDL subsidy does not apply to ezetimibe/simvastatin 10/10 mg or 10/20 mg tablets. Quicklinks | | | | | Copyrights © 2019 Ministry of Health, Singapore. Last Updated on 2 May 2019

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

3. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. (PubMed)

Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. Limited evidence is available regarding the benefit and hazard of higher-intensity treatment to lower lipid levels among patients 75 years or older. As a result, guideline recommendations differ for this age group compared with younger patients.To determine the effect on outcomes and risks of combination (...) ezetimibe and simvastatin compared with simvastatin monotherapy to lower lipid levels among patients 75 years or older with stabilized acute coronary syndrome (ACS).In this prespecified secondary analysis of the global, multicenter, prospective clinical randomized Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), outcomes and risks were compared by age among patients 50 years or older after a hospitalization for ACS. Data were collected from October 26, 2005, through

Full Text available with Trip Pro

2019 JAMA cardiology Controlled trial quality: predicted high

4. Adjunctive simvastatin for treatment-resistant depression: study protocol of a 12-week randomised controlled trial. (PubMed)

Adjunctive simvastatin for treatment-resistant depression: study protocol of a 12-week randomised controlled trial. A third of patients diagnosed with major depressive disorder (MDD) experience treatment-resistant depression (TRD). Relatively few pharmacological agents have established efficacy for TRD. Therefore, the evaluation of novel treatments for TRD is a pressing priority. Statins are pleiotropic agents and preclinical studies as well as preliminary clinical trials have suggested (...) that these drugs may have antidepressant properties.AimsTo report on a protocol for a 12-week, randomised, double-blind, placebo-controlled trial of add-on treatment with simvastatin for patients meeting DSM-5 criteria for MDD who have failed to respond to at least two adequate trials with approved antidepressants. The trial has been registered with Clinicaltrials.gov in (ClinicalTrials.gov identifier: NCT03435744).After screening and randomisation to the two parallel arms of the trial, 75 patients

Full Text available with Trip Pro

2019 BJPsych open Controlled trial quality: predicted high

5. Simvastatin

Simvastatin Top results for simvastatin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for simvastatin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

6. Simvastatin to reduce pulmonary dysfunction in patients with acute respiratory distress syndrome: the HARP-2 RCT

Simvastatin to reduce pulmonary dysfunction in patients with acute respiratory distress syndrome: the HARP-2 RCT Simvastatin to reduce pulmonary dysfunction in patients with acute respiratory distress syndrome: the HARP-2 RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This study showed that simvastatin did not increase the number of ventilator-free days or improve mortality in patients with acute respiratory distress syndrome. {{author}} {{($index , , , , , , , , , , , , & . Daniel F McAuley 1, 2, 3, * , John G Laffey 4 , Cecilia M O’Kane 1 , Gavin D Perkins 5, 6 , Brian Mullan 2 , Thomas J Trinder 7 , Paul Johnston 8 , Phillip A Hopkins 9

2018 NIHR HTA programme

7. Efficacy and safety of simvastatin in the primary and secondary prevention on patients with cardiovascular disease, hyperlipidemia and type 2 diabetes mellitus: a systemic review and meta-analysis

Efficacy and safety of simvastatin in the primary and secondary prevention on patients with cardiovascular disease, hyperlipidemia and type 2 diabetes mellitus: a systemic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2018 PROSPERO

8. How to balance the benefits on cardiovascular outcome and the risk on rising glucose levels of Simvastatin as a secondary prevention treatment among patients with coronary heart disease: systematic review and meta-analysis based on RCTs and observational

How to balance the benefits on cardiovascular outcome and the risk on rising glucose levels of Simvastatin as a secondary prevention treatment among patients with coronary heart disease: systematic review and meta-analysis based on RCTs and observational Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content

2018 PROSPERO

9. How to balance the benefits on cardiovascular outcome and the risk on rising glucose levels of Simvastatin as a primary prevention treatment among hyperlipidemia patients: systematic review and meta-analysis based on RCTs and observational studies

How to balance the benefits on cardiovascular outcome and the risk on rising glucose levels of Simvastatin as a primary prevention treatment among hyperlipidemia patients: systematic review and meta-analysis based on RCTs and observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content

2018 PROSPERO

10. The incidence of the main adverse events of Simvastatin among patients with coronary heart disease, hyperlipidemia or type 2 diabetes mellitus: systematic review and meta-analysis based on RCTs and observational studies

The incidence of the main adverse events of Simvastatin among patients with coronary heart disease, hyperlipidemia or type 2 diabetes mellitus: systematic review and meta-analysis based on RCTs and observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any

2018 PROSPERO

11. Rethinking the effect on blood glucose of Simvastatin among patients with type 2 diabetes mellitus: systematic review and meta-analysis based on RCTs and observational studies

Rethinking the effect on blood glucose of Simvastatin among patients with type 2 diabetes mellitus: systematic review and meta-analysis based on RCTs and observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2018 PROSPERO

12. Local effects of calcium phosphate as a carrier of simvastatin on bone regeneration. A systematic review

Local effects of calcium phosphate as a carrier of simvastatin on bone regeneration. A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO

13. The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin (PubMed)

The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin Between 2010 and 2012, the US Food and Drug Administration and Health Canada issued warnings to healthcare professionals emphasizing the increased risk of muscle problems with high-dose simvastatin.To measure the impact of the Health Canada safety warning regarding dose-dependent adverse effects of simvastatin on prescribing of low, medium, and high doses of simvastatin.An interrupted time-series (...) design was used to evaluate the impact of a Health Canada safety warning on 7 November 2012 regarding the safety of high-dose simvastatin. Monthly prescription records were analyzed for beneficiaries of the Nova Scotia Seniors' Pharmacare Program aged 65 years or older who had received > 1 prescription of simvastatin between 1 January 1997 and 31 March 2015. Autoregressive Integrated Moving Average models were used to test changes in the proportion of beneficiaries dispensed a low dose (< 40 mg

Full Text available with Trip Pro

2017 Drugs - real world outcomes

14. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy (...) , in which we investigated the treatment effect on cognitive, neuropsychiatric, and health-related quality-of-life (HRQoL) outcome measures.We did a secondary analysis of MS-STAT, a 24-month, double-blind, controlled trial of patients with SPMS done at three neuroscience centres in the UK between Jan 28, 2008, and Nov 4, 2011. Patients were randomly assigned (1:1) to either 80 mg simvastatin (n=70) or placebo (n=70). The cognitive assessments done were the National Adult Reading Test, Wechsler

Full Text available with Trip Pro

2017 EvidenceUpdates

15. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis (PubMed)

Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis The combination of β-blockers and band ligation is the standard approach to prevent variceal rebleeding, but bleeding recurs and mortality is high. The lipid-lowering drug simvastatin decreases portal pressure, improves hepatocellular function, and might reduce liver fibrosis. We assessed whether adding simvastatin to standard therapy (...) could reduce rebleeding and death after variceal bleeding in patients with cirrhosis.We performed a multicenter, double-blind, parallel trial of 158 patients with cirrhosis receiving standard prophylaxis to prevent rebleeding (a β-blocker and band ligation) in Spain from October 2010 through October 2013. Within 10 days of bleeding, subjects were randomly assigned, but stratified by Child-Pugh class of A or B vs C, to groups given simvastatin (20 mg/d the first 15 days, 40 mg/d thereafter; n = 69

Full Text available with Trip Pro

2016 EvidenceUpdates Controlled trial quality: predicted high

16. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP) (PubMed)

Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP) Simvastatin, 20mg, plus ezetimibe, 10mg, daily (simvastatin plus ezetimibe) reduced major atherosclerotic events in patients with moderate to severe chronic kidney disease (CKD) in the Study of Heart and Renal Protection (SHARP), but its cost-effectiveness is unknown.Cost-effectiveness of simvastatin plus ezetimibe in SHARP, a randomized controlled (...) trial.9,270 patients with CKD randomly assigned to simvastatin plus ezetimibe versus placebo; participants in categories by 5-year cardiovascular risk (low, <10%; medium, 10%-<20%; or high, ≥20%) and CKD stage (3, 4, 5 not on dialysis, or on dialysis therapy).Assessment during SHARP follow-up from the UK perspective; long-term projections.Simvastatin plus ezetimibe (2015 UK £1.19 per day) during 4.9 years' median follow-up in SHARP; scenario analyses with high-intensity statin regimens (2015 UK

Full Text available with Trip Pro

2016 EvidenceUpdates Controlled trial quality: uncertain

17. Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT (PubMed)

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP); addition of ezetimibe to statins further reduces LDL-C and hs-CRP. An analysis of the relationship between achieved LDL-C and hs-CRP targets and outcomes for simvastatin (...) and ezetimibe/simvastatin was prespecified in Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).The IMPROVE-IT trial randomly assigned 18 144 patients stabilized after acute coronary syndrome to simvastatin or ezetimibe/simvastatin. LDL-C and hs-CRP were measured at baseline and 1 month after randomization. Outcomes were assessed in those achieving one or both of the prespecified targets of LDL-C<70 mg/dL and hs-CRP<2 mg/L versus achieving neither target, adjusting

Full Text available with Trip Pro

2015 EvidenceUpdates Controlled trial quality: uncertain

18. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease (PubMed)

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease To study whether high-dose versus usual-dose statin treatment reduces the incidence of peripheral artery disease (PAD) and what is the effect of high-dose statin treatment on cardiovascular disease (CVD) outcome in patients with PAD.In the Incremental Decrease in End Points Through Aggressive Lipid Lowering trial, 8888 post-myocardial infarction patients were randomised to high-dose (...) or usual-dose statin therapy (atorvastatin 80 mg/day vs simvastatin 20-40 mg/day). We investigated the effect of high-dose versus usual-dose statins on the pre-specified outcome PAD incidence, and additionally performed a posthoc analysis of the efficacy of high-dose statins in reducing CVD risk among patients with PAD. During a median follow-up of 4.8 years, 94 patients (2.2%) receiving atorvastatin and 135 patients (3.2%) receiving simvastatin developed PAD (HR=0.70, 95% CI 0.53 to 0.91; p=0.007

2015 EvidenceUpdates Controlled trial quality: uncertain

19. Simvastatin in the Acute Respiratory Distress Syndrome

Simvastatin in the Acute Respiratory Distress Syndrome PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2014 PedsCCM Evidence-Based Journal Club

20. Simvastatin in the acute respiratory distress syndrome. (PubMed)

Simvastatin in the acute respiratory distress syndrome. Studies in animals and in vitro and phase 2 studies in humans suggest that statins may be beneficial in the treatment of the acute respiratory distress syndrome (ARDS). This study tested the hypothesis that treatment with simvastatin would improve clinical outcomes in patients with ARDS.In this multicenter, double-blind clinical trial, we randomly assigned (in a 1:1 ratio) patients with an onset of ARDS within the previous 48 hours (...) to receive enteral simvastatin at a dose of 80 mg or placebo once daily for a maximum of 28 days. The primary outcome was the number of ventilator-free days to day 28. Secondary outcomes included the number of days free of nonpulmonary organ failure to day 28, mortality at 28 days, and safety.The study recruited 540 patients, with 259 patients assigned to simvastatin and 281 to placebo. The groups were well matched with respect to demographic and baseline physiological variables. There was no significant

Full Text available with Trip Pro

2014 NEJM Controlled trial quality: predicted high